http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2022000167-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_aba919a772df92cccc656ce434ce0660 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_77ee80fc15abd629c420d0bf068d0e06 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-177 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-02 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-17 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-40 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-14 |
| filingDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_cda0770b4abbb7a37327bb8168abfc78 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_286ce2a87038dc4065dfde1a3e20c0d9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5dedf3153b2f355c41f02329a640cbf6 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_46f4f9b962e661f24be648cd83888b2d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_58c53f602c81d1dd1255636f6bbcbde0 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fbb37f8f3f9b6dbdfa9c07adf89cd2d |
| publicationDate | 2022-01-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | WO-2022000167-A1 |
| titleOfInvention | Use of transferrin, transferrin receptor and antibody thereof in preparation of drug for resisting sars-cov-2 virus |
| abstract | Provided in the present invention is the use of transferrin, a transferrin receptor and an antibody thereof in the preparation of a drug for resisting SARS-CoV-2 virus, which belongs to the technical field of antiviral drugs. Provided is the use of transferrin, a transferrin receptor or a transferrin receptor antibody in the preparation of a drug for resisting SARS-CoV-2. Both surface plasmon resonance and immunofluorescence prove that SARS-CoV-2 binds to the transferrin receptor by means of a spike protein thereof, and the transferrin and/or the transferrin receptor antibody competitively bind/binds to the transferrin receptor of an organism, or the transferrin receptor competitively binds to a site of the SARS-CoV-2 to inhibit the binding of the SARS-CoV-2 to the transferrin receptor of the organism, thereby blocking the chance of infecting cells by the SARS-CoV-2 virus and achieving the antiviral effect of the organism. Further provided is the use of transferrin, a transferrin receptor and an antibody thereof in the preparation of a biological product combined with a spike protein of the SARS-CoV-2 virus. |
| priorityDate | 2020-06-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
| Predicate | Subject |
|---|---|
| isDiscussedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID226399992 http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID2719 |
Total number of triples: 27.